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Abstract
BACKGROUND—The extent to which medical oncologists consider non-clinical patient factors 
when deciding to recommend adjuvant chemotherapy is unknown.
METHODS—Medical oncologists who treated a population-based sample of early-stage breast 
cancer patients reported to the Los Angeles and Detroit Surveillance, Epidemiology, and End 
Results registries 2005–2007 were asked how strongly they consider a patient’s ability to follow 
instructions, level of social support, and level of work support/flexibility in decisions to 
recommend adjuvant chemotherapy. Responses of 4 (Quite strongly) or 5 (Very strongly) on a 5-
point Likert scale defined strong consideration. Associations between oncologist/practice 
characteristics and strong consideration of each non-clinical factor were examined.
RESULTS—134 oncologists (66%) reported strong consideration of one or more factor. Ability 
to follow instructions was strongly considered by 120 oncologists (59%), social support by 78 
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(38%), and work support/flexibility by 73 (36%). Larger percent of practice devoted to breast 
cancer was associated with lower likelihood of strongly considering ability to follow instructions 
[odds ratio (OR) 0.98, 95% confidence interval (CI) 0.97–0.99; P=0.04]. Increased years in 
practice was associated with lower likelihood of strongly considering social support (OR 0.96, CI 
0.93–0.99; P=0.011), while non-white race (OR 2.1, CI 1.03–4.26; P=0.041) and tumor board 
access (OR 2.04, CI 1.01–4.12; P=0.048) were associated with higher likelihood. Non-white race 
was associated with strongly considering work support/flexibility (OR 2.44, CI 1.21–4.92; 
P=0.013). Tumor board access (OR 2, CI 1.00–4.02; P=0.051) was borderline significant.
CONCLUSIONS—Non-clinical patient factors play a role in medical oncologist decision-making 
for breast cancer adjuvant chemotherapy recommendations.
Keywords
decision making; breast cancer; chemotherapy; social environment; socioeconomic factors
Introduction
Oncologist recommendations for adjuvant chemotherapy for patients with breast cancer are 
based on numerous factors, including patient clinical factors and tumor characteristics. In 
breast cancer patients with a high risk of recurrence by virtue of stage or tumor biology, 
guidelines recommend treatment with adjuvant chemotherapy in the absence of substantial 
patient comorbidity [1]. For patients with a lower risk of recurrence and a corresponding 
lower marginal benefit of adjuvant chemotherapy [2,3], factors such as patient preferences 
and physician beliefs about the benefit of chemotherapy enter into the treatment decision [4–
6].
It is not known to what extent non-clinical patient factors play a role in medical oncologists' 
recommendations regarding chemotherapy. In other medical conditions, including diabetes 
and cardiovascular disease, factors such as presence of social support, heavy career and 
family demands, a patient’s desire for an active lifestyle, and perceived patient education 
level have been shown to influence physician treatment recommendations [7–9]. Primary 
care providers have reported that patient socioeconomic status affects their clinical 
management decisions including diagnostic testing, medication prescription, and referrals to 
subspecialists [5,10]. In other work, social, behavioral, and psychological patient 
characteristics influence physician decision to recommend initiation of protease inhibitor 
triple combination regimens for the treatment of HIV/AIDS [11]. In some of these clinical 
settings, physician demographic characteristics, including sex and race, have been associated 
with the tendency to consider these non-clinical factors [6].
The purpose of this study was to investigate the extent to which medical oncologists 
consider non-clinical patient factors (ability to follow instructions, level of social support, 
and level of support and flexibility at work) in their decisions to recommend adjuvant 
chemotherapy for breast cancer. These three factors were chosen because of the potential of 
each to affect the successful delivery of a complete course of adjuvant chemotherapy. As 
described in greater detail below in Methods, we hypothesized that physician and practice 
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characteristics would be associated with the degree to which medical oncologists consider 
each non-clinical factor.
Methods
Study Sample and Data Collection
Medical oncologists who treated a population-based sample of patients diagnosed with 
early-stage invasive breast cancer in the Los Angeles and Detroit Surveillance, 
Epidemiology, and End Results (SEER) registries were invited to complete a survey. Details 
of the patient survey have been previously published [12,13]. The patient survey was 
administered to patients diagnosed between 2005 and 2007, approximately 9 months after 
diagnosis. Patient participants were asked to identify their medical oncologist. The 
oncologist sample was augmented by identifying additional medical oncologists through the 
Los Angeles County Cancer Surveillance Program (n = 43). The oncologists were mailed a 
letter of introduction, survey, and $40 gift incentive. A modified version of the Dillman 
method was used to optimize response rate. Follow-up of non-respondents included a 
postcard reminder and then a telephone reminder [14].
The Institutional Review Boards of the University of Michigan, University of Southern 
California, and Wayne State University approved all study procedures.
Measures
The measures used in this analysis were obtained from the medical oncologist survey.
Dependent variables—On a 5-point Likert scale (“not at all” to “very strongly”), 
oncologists were asked to rate how strongly they consider the following non-clinical patient 
factors when deciding whether or not to recommend adjuvant chemotherapy to patients with 
breast cancer: (1) ability to follow instructions, (2) level of social support, and (3) level of 
support and flexibility at work. Non-clinical factors were defined as being “strongly 
considered” if the oncologists indicated 4 (quite strongly) or 5 (very strongly) on the Likert 
scale. Responses of 1 to 3 were categorized as “not strongly considered.”
Independent variables—Oncologist characteristics included years in practice, percent of 
practice devoted to breast cancer, and percent of patients with Medicaid (continuous 
variables), and sex, race, nights per week personally on-call, and frequency of evaluation of 
patients during chemotherapy (categorical variables). Response options for race included 
white, African-American, American Indian or Alaska native, Asian or Pacific Islander, and 
other, and was categorized as “white” versus “other” because of the small number of 
oncologists in each of the non-white groups. Responses for frequency of evaluation of 
patients during chemotherapy included before each cycle, before most cycles, before some 
cycles, and only before the first and after the last cycle, and was categorized as before each 
cycle versus other. For nights per week personally on-call, oncologists responded less than 
one night, one night, two to three nights, or four or more nights. This variable was 
categorized as one night or less versus two or more. Practice characteristics (yes/no) 
included availability of social workers and/or psychologists, university affiliation, 
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availability of nurse practitioners and/or physician assistants to see patients during 
chemotherapy, access to a tumor board, feedback to clinicians about meeting clinical 
management standards, and participation in a regional and/or national network to examine 
variations in treatment.
Because of the potential for higher perceived work burden for the oncologist to respond to 
and treat side effects were they to develop, we hypothesized that more nights personally on-
call, higher frequency of evaluation of patients during the course of chemotherapy treatment, 
lack of social workers and/or psychologists and nurse practitioners and/or physician 
assistants, and a larger percent of patients being seen in the practice with Medicaid insurance 
would be associated with strong consideration of non-clinical patient factors. We 
hypothesized that access to tumor board conferences would also be associated with strong 
consideration. Tumor boards are typically attended by a variety of healthcare providers, 
including medical, surgical, and radiation oncologists, social workers, psychologists, and 
genetic counselors. Many tumor boards are held before medical oncologists meet patients 
for an initial consultation, and may heighten provider awareness of non-clinical patient 
factors that could affect the course of chemotherapy delivery. Conversely, we hypothesized 
that more years in practice and a larger percent of practice devoted to breast cancer 
(reflecting specialization and greater degree of confidence in ability to manage treatment 
toxicities), and feedback regarding management standards and participation in a network to 
examine treatment variation (providing clearly defined treatment guidelines), would 
decrease the impact of non-clinical factors on treatment recommendations.
Statistical Analyses
We calculated the percent of medical oncologists who strongly considered each of the non-
clinical patient factors (ability to follow instructions, level of social support, level of work 
support and flexibility) separately. We also created a variable reflecting the count (0 to 3) of 
the total number of non-clinical patient factors strongly considered by each oncologist, and 
we calculated the percent of oncologists who considered 0, 1, 2 or 3 non-clinical factors. 
Respondents who did not answer all three of the dependent variable questions (n = 2) were 
excluded from these analyses.
For each of the three non-clinical patient factors, we performed separate bivariate analyses to 
compare oncologist and practice characteristics between those oncologists who reported 
strong consideration of each factor and those who did not. Two-sided t-tests were used to 
compare continuous variables, and Pearson chi-squared tests were used to compare 
categorical variables. Due to missing data, one oncologist was excluded from the ability to 
follow instructions analyses, and one oncologist was excluded from the work support and 
flexibility analyses.
We defined three multivariate logistic regression models to investigate associations between 
the oncologist and practice characteristics and strong consideration of each of the three non-
clinical patient factors. Each model included only those oncologist and practice factors 
determined to be significant at a P-value of less than 0.25 in the bivariate analyses [15]. All 
three models controlled for sex, race, years in practice, and percent of patients with 
Medicaid. We also controlled for availability of social worker(s) or psychologist(s) in the 
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two models that examined associations with level of social support and level of work support 
and flexibility. Rates of missing variables ranged from 0 to 9%. Oncologists for whom we 
were missing independent variables were excluded from the analytic samples. Among the 
three models, up to 16.6% of the oncologists were excluded. Therefore, sensitivity analyses 
were conducted where missing values were multiply imputed to correct for potential missing 
data bias. Estimates and their variances from the multiple imputation results were combined 
according to the Rubin method [16].
Statistical significance was defined at a type I error rate of less than 5%. STATA/SE 11 
(StataCorp LP, College Station, TX) was used for all statistical analyses.
Results
Description of oncologist sample
A total of 262 medical oncologists were identified by the patient respondents. Of these 
oncologists, 180 (69%) completed the survey. An additional 43 medical oncologists were 
identified through the Los Angeles County Cancer Surveillance Program, and 26 (60%) of 
these completed the survey. In total, 206 oncologists completed the survey (combined 
response rate of 67.5%). One oncologist indicated that s/he did not see any breast cancer 
patients and was excluded.
Table 1 shows the characteristics of the 205 oncologists. Respondents reported having a 
median of 30% of their practice devoted to breast cancer patients, and five (3%) of the 
oncologists had a practice devoted to exclusively to breast cancer patients. The estimated 
percent of patients with Medicaid insurance in the oncologists’ practices varied from 0% to 
70% with a median of 10%. Approximately one-half of the oncologists reported having a 
nurse practitioner and/or physician assistant who evaluate patients during chemotherapy 
(54%), but most did not have a social worker and/or psychologist available to see patients 
(80%). Over half of the oncologists (58%) reported receiving feedback regarding meeting 
clinical management standards; fewer (44%) worked in practices that participate in a 
regional and/or national network to examine treatment variations.
Outcome measures
Overall, 134 oncologists (66% of 203) reported strong consideration of one or more non-
clinical factor when deciding to recommend adjuvant chemotherapy for breast cancer. One 
hundred twenty oncologists (59%) strongly consider a patient’s ability to follow instructions, 
78 (38%) strongly consider patient level of social support, and 73 (36%) strongly consider 
patient level of support and flexibility at work (Figure 1). Responses were not mutually 
exclusive.
In aggregate, oncologists reported strongly considering a median of one non-clinical patient 
factor, with a range of none to all three. Forty-eight oncologists (24%) indicated that they 
strongly consider all three of the non-clinical factors. Of the remaining oncologists, 39 
(19%) indicated strong consideration of two of the non-clinical factors, 47 (23%) indicated 
strong consideration of one, and 69 oncologists (34%) reported none (Figure 2).
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Among oncologists reporting strong consideration of level of social support as compared to 
those who did not, the average number of years in practice was lower (16.3 years versus 
20.6, P = 0.009) and a larger percent reported access to tumor board (62% versus 55%, 
P=0.045). Among oncologists reporting strong consideration of level of work support and 
flexibility, there was a higher percent who reported receiving feedback about meeting 
clinical management standards (67% versus 53%, P=0.045) and access to tumor board (73% 
versus 53%, P=0.007). There was a higher proportion of oncologists of non-white race 
among those reporting strong consideration of level of social support (49% versus 31%, 
P=0.006) as well as among those reporting strong consideration of level of work support and 
flexibility (50% versus 32%, P=0.022). All other bivariate comparisons were not statistically 
significant.
Multivariate Analyses
Results from the three multivariate models investigating associations between oncologist and 
practice characteristics and strong consideration of each of the three non-clinical patient 
factors are presented in Table 2. In the first model, a patient’s ability to follow instructions 
was less likely to be strongly considered amongst the oncologists with a larger percentage of 
their practice devoted to breast cancer (OR 0.98, 95% CI 0.97–0.99; P=0.04). The second 
model demonstrated that level of social support was less likely to be strongly considered by 
oncologists with more years in practice (OR 0.96, 95% CI 0.93–0.99; P=0.011), and more 
likely to be strongly considered by oncologists who were of non-white race (OR 2.1, 95% CI 
1.03–4.26; P=0.041) and those with access to a tumor board (OR 2.04, 95% CI 1.01–4.12; 
P=0.048). In the third model, level of work support and flexibility was more likely to be 
strongly considered by non-white oncologists (OR 2.44, 95% CI 1.21–4.92; P=0.013). 
Access to a tumor board was borderline significant in this model (OR 2, 95% CI 1.00–4.02; 
P=0.051). In all three models, none of the other oncologist or practice characteristics 
included were associated with strong consideration of the non-clinical patient factors.
Sensitivity Analyses
Analyses with and without multiple imputation (MI) yielded generally consistent findings 
except for a few small changes in associations. In the model investigating factors associated 
with strong consideration of level of work support and flexibility, the effect of access to 
tumor board became larger and statistically significant (without MI OR = 2, 95% CI 1.00–
4.02, P = 0.051; with MI OR = 2.75, 95% CI 1.31–4.88, P = 0.006) and the effect of non-
white race became smaller and less statistically significant (without MI OR = 2.44, 95% CI 
1.21–4.92, P = 0.013; with MI OR = 1.83, 95% CI 0.96–3.58, P = 0.068).
Discussion
In summary, we found that medical oncologists frequently report consideration of non-
clinical patient factors in their decisions to recommend breast cancer adjuvant 
chemotherapy, with two-thirds of oncologists reporting strong consideration of one or more 
non-clinical factor. Oncologists reported strong consideration of a patient’s ability to follow 
instructions at a higher frequency than level of support. This may be due to a perception that 
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ability to follow instructions has a greater direct impact on the successful delivery of a 
course of adjuvant chemotherapy than the patient’s support environment. Alternatively, 
oncologists may place more emphasis on ability to follow instructions because they have 
greater confidence in being able to accurately assess this as compared to a patient’s social 
environment.
The associations between years in practice and consideration of a patient’s ability to follow 
instructions, and extent of specialization in breast cancer and consideration of level of social 
support, may be the result of greater physician experience and confidence in his/her ability 
to support the patient through chemotherapy treatment regardless of these non-clinical 
patient factors. Our finding that physicians with more experience are less likely to 
incorporate these non-clinical factors may partly explain previous research on the 
relationship between years in practice and patient outcomes [17,18].
The association between tumor board availability and strong consideration of social support 
and work support and flexibility may be related to an enhanced awareness of social 
vulnerability of patients. In clinical vignette studies, social vulnerability has been shown to 
play a role in treatment recommendation decision-making. For example, in one study, black 
men and those who were former injection drug users were rated by physicians as less likely 
to adhere to highly active antiretroviral therapy (HAART) for HIV. This perception was 
associated with a lower likelihood that the responding physician would prescribe HAART 
[19]. In another study using written vignettes describing patients with prostate cancer, 
urologists were less likely to recommend a radical prostatectomy to patients who were 
described as low-income and widowed compared to those who were middle-income and 
married [20]. Multidisciplinary tumor boards are a forum in which multiple providers 
describe patient cases, often including descriptions of behavioral and social issues. 
Discussions about patients’ financial and social challenges before a medical oncologist 
meets a patient may heighten awareness of issues that are perceived as impacting whether or 
not a patient will actively seek supportive care during chemotherapy.
Although we observed an association between non-white oncologist race and greater 
likelihood of strongly considering level of social support and level of work support and 
flexibility, the non-white race group was heterogeneous. Further work investigating the 
relationship between physician race and the role that non-clinical patient factors play in 
decisions to recommend adjuvant chemotherapy for breast cancer treatment may be 
warranted.
Our findings could be interpreted as evidence that medical oncologists are providing patient-
centered care. According to the Institute of Medicine, provision of patient-centered care 
requires that physicians must know the patient as a whole person, including the social 
circumstances and ability to follow instructions [21]. However, in order for patient-centered 
care to result in desirable outcomes, the physician assessment of these non-clinical factors 
and the impact these non-clinical factors will have on treatment delivery must be accurate. 
The issue is further complicated because decisions to recommend adjuvant chemotherapy 
are, by definition, made under conditions of uncertainty since the degree of benefit achieved 
in an individual patient is uncertain [22]. Therefore, consideration of non-clinical patient 
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factors could incorrectly result in adjuvant chemotherapy not being recommended in patients 
with a higher risk of recurrence for whom treatment offers greater benefit.
This study has several limitations. First, a limited number of medical oncologists in only two 
areas of the country were surveyed. Respondents may not be representative of all the 
medical oncologists in the Detroit and Los Angeles SEER catchment areas. Second, it is 
possible that the degree of consideration of non-clinical factors was overestimated because 
medical oncologists felt that to consider non-clinical patient factors is the socially desirable 
response. Third, we do not know whether oncologists’ survey responses correspond to their 
actual practice patterns. Finally, the analyses were not specifically powered to detect 
significant associations for all of the medical oncologist and practice characteristics being 
investigated. Thus, caution should be exercised when interpreting the non-significant 
findings.
The rates of missing data differed across gender, race and participation in a practice network 
to examine treatment variation. To reduce potential missing data bias, we performed 
multiple imputation on the missing values [23]. This allowed us to include all 204 
oncologists in our analyses to gain efficiency and be able to generalize the conclusions to the 
original sample population. The multiple imputation results are similar to the analyses 
limited to oncologists with complete data. Although the association between access to a 
tumor board and non-white race with level of work support and flexibility change slightly 
after imputation, the directions of all associations were consistent with and without multiple 
imputation, and both factors remain significantly associated with strong consideration of 
support and flexibility at work.
Quality of care is affected by errors of omission that result from failure to provide indicated 
treatments [24]. Consideration of non-clinical patient factors may increase errors of 
omission due to inaccurate assessment of a patient’s true social context and incorporation of 
these non-clinical patient factors into decisions whether or not to recommend adjuvant 
chemotherapy treatment in cases where they should not be considered. Decisions made by 
medical oncologists to recommend adjuvant chemotherapy are not made over time. Rather, 
they are made after one or, at most, two patient-provider encounters. Decisions that 
incorporate non-clinical factors after few meetings with the patient are prone to error. In a 
study of simulated first-encounter primary care office visits, 88% of the physicians made 
what are referred to as “contextual errors” in which they did not adequately assess a patient's 
environment or behavior (context) when faced with complicated scenarios [25]. 
Furthermore, tumor boards provide the opportunity for medical oncologists to be primed 
with potentially inaccurate information about a patient’s social situation even prior to 
meeting the patient. Therefore, in the setting of adjuvant chemotherapy decision-making, 
errors in assessment of a patient’s context may significantly increase the risk of omission of 
important therapy. The use of assessment tools to identify patients who have problems 
following instructions, and those with minimal support, may increase the accuracy of 
oncologists’ knowledge of a patient’s social context. Incorporating tools such as these into a 
healthcare system in which individual providers and practices are prepared to meet the needs 
of patients whom providers perceive to be at risk during chemotherapy will improve the 
quality of cancer care.
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Percent of oncologists reporting strong consideration of non-clinical patient factors* (N = 
203)
*Not mutually exclusive
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Percent of medical oncologists by count of total number of non-clinical patient factors 
strongly considered (N = 203)
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Table 1
Medical oncologist respondent characteristics (N = 205)
Characteristic
Median Range
Years in practice 20 1 – 51
% of practice devoted to breast cancer 30 1 – 100
% of patients Medicaid 10 0 – 80
No. %
Sex
  Male 152 74.1
  Female 50 24.4
  Missing 3 1.5
Race/Ethnicity
  White 120 58.5
  Other 77 37.6
  Missing 8 3.9
Nights per week personally on-call
  One or less 82 40.0
  Two or more 123 60.0
Frequency of evaluation of patients during chemotherapy
  Less than prior to each cycle 63 29.3
  Prior to each cycle 143 69.8
  Missing 2 0.9
Availability of social workers and/or psychologists
  No 163 79.5
  Yes 42 20.5
University affiliation
  No 136 66.3
  Yes 68 33.2
  Missing 1 0.5
Availability of nurse practitioners and/or physician assistants
  No 95 46.3
  Yes 110 53.7
Access to a tumor board
  No 81 39.5
  Yes 124 60.5
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Characteristic
Median Range
Feedback to clinicians about meeting clinical management standards
  No 86 41.9
  Yes 119 58.1
Participation in a regional and/or national network to examine treatment variations
  No 111 54.1
  Yes 90 43.9
  Missing 4 1.9
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